Efficacy of modified enfortumab vedotin ineligible criteria (mEVITA) in advanced urothelial carcinoma

Efficacy of modified enfortumab vedotin ineligible criteria (mEVITA) in advanced urothelial carcinoma

Abstract Enfortumab Vedotin Ineligible criTeriA (EVITA) were proposed for the selection of patients to receive enfortumab vedotin (EV) and pembrolizumab treatment. However, the usefulness of these criteria has not been fully verified. We retrospectively analyzed data from 301 patients with unresecta...

Full description

Saved in:
Bibliographic Details
Main Authors: Takafumi Fukushima, Kazuyuki Numakura, Masanao Shinohara, Yohei Kawashima, Yuya Sekine, Kanami Mori, Mizuki Kobayashi, Himawari Asanuma, Takaki Ichiyama, Hisashi Sakurai, Kai Ozaki, Naoki Fujita, Teppei Okamoto, Hayato Yamamoto, Takahiro Yoneyama, Satoshi Sato, Tomonori Habuchi, Chikara Ohyama, Shingo Hatakeyama
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Scientific Reports
Subjects:
Efficacy
Enfortumab Vedotin
EVITA
Safety
Urothelial carcinoma
Online Access:https://doi.org/10.1038/s41598-025-09806-1
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-09806-1

Similar Items